FDA Approves Treatment for Anemia in Adults with Rare Inherited Disorder

News
Article

FDA has approved Pyrukynd (mitapivat) tablets to treat hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

FDA announced on Feb. 17, 2022 that Pyrukynd (mitapivat) tablets are approved to treat hemolytic anemia, a disorder in which red blood cells are destroyed faster than they can be made, in adults with pyruvate kinase (PK) deficiency

PK is a rare and inherited disorder that causes premature red blood cell destruction, which leads to anemia (a decreased number of red blood cells.) PK deficiency is frequently misdiagnosed or undiagnosed. Patients with PK deficiency can experience a range in severity of symptoms, which can include fatigue, unusually pale skin, jaundice (yellowing of skin and eyes), shortness of breath, and a fast heart rate.

Mitapivat’s effectiveness was evaluated in two studies; one randomized, double-blind, placebo-controlled clinical study of 80 adults with PK deficiency who did not receive regular blood transfusions, and one single-arm study of 27 adults with PK deficiency who received regular blood transfusions. The randomized study rated the treatment’s effectiveness on hemoglobin (a measure of the amount of red blood cells that are not destroyed) response, while the single-arm study based its effectiveness on reduction in transfusion burden, defined as at least a 33% reduction in the number of red blood cell units transfused during the last 24 weeks of treatment compared with the historical transfusion burden on the individual participant (standardized to 24 weeks).

At the end of the randomized study, 40% of participants receiving mitapivat had a hemoglobin response compared with no participants receiving placebo. At the end of the single-arm study, 33% of participants receiving mitapivat experienced the reduction in transfusion burden, including 22% of participants who did not require any transfusions during the last 24 weeks of treatment.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes